Group items tagged

The Department of Health (DoH) in Northern Ireland has published a new Strategic Plan for Community Pharmacy, highlighting the vision and key priorities for the sector over the next 10 years. Co-developed by the DoH and Community Pharmacy Northern Ireland (CPNI), the representative body for community pharmacy owners, the plan aims to fully realise the potential of community pharmacy services to support better health outcomes from medicines and prevent illness. The vision outlined in the plan sees community pharmacies offering more clinical services, leveraging the skills of their teams to provide the public with safe, convenient, and faster access to care. According to DOH, the vision will be realised through four major reform programmes focusing on services, legislation, workforce, and digital enablers, alongside six strategic priorities. Together, these initiatives are anticipated to transform the role of community pharmacy within the Health and Social Care (HSC). Health Minister Robin Swann has extended his support to the new Community Pharmacy Strategic Plan, which builds on the previously agreed 3-year community pharmacy commissioning plan.

O'Briens Pharmacy Group has sold Bispham Pharmacy as part of a strategic review of its nine-site portfolio, now reduced to eight, across the Fylde coast region. Christie and Co, the property adviser, recently announced that the group's popular Blackpool pharmacy business has been acquired by first-time buyer, Arif Bhuriya. Bispham Pharmacy, which dispenses around 4,500 items per month, is situated in the heart of Bispham's commercial centre, opposite a bustling shopping area. The community pharmacy has been in this location since February 2021, following a minor contract relocation. O'Briens Pharmacy Group provides pharmacy services across Fleetwood, Thornton-Cleveleys, Bispham, Burscough, Liverpool, and surrounding areas. Aisling O'Brien, owner of O'Briens Pharmacy, explained the rationale behind selling the Bispham site: "When we had a strategic review of our group, we saw Bispham as an ideal site to dispose of, knowing it would fare much better in the current climate as an owner-operated site.

Consumer goods giant Unilever signalled on Monday (January 17) it would pursue a deal for GlaxoSmithKline's consumer healthcare business, calling it a "strong strategic fit" after its £50 billion offer was refused. GSK confirmed on Saturday that it had rejected three approaches from the Dove-soap maker, adding it intended to stick to its own plan to spin off the business as a separate company later this year. "GSK Consumer Healthcare would be a strong strategic fit," Unilever said in a statement as it unveiled a strategy update in the wake of the weekend's takeover news. Unilever said it was "committed to accelerating the company's growth and repositioning the portfolio into higher growth categories. "As a result of the reporting of Unilever's interest in GSK Consumer Healthcare, we are today bringing forward a planned update, setting out the strategic direction that the company is pursuing," Unilever said.

The Department of Health (DoH) is inviting the public to share their views on a new Regional Obesity Management Service and a new Obesity Strategic Framework. A public consultation has been launched on the Healthy Futures strategic framework, which aims to prevent the harm caused by obesity, and improve diets and levels of physical activity of people. The Department is also seeking views on its plans to introduce a new service that would focus on the introduction of specialist support, weight loss medication, and bariatric surgery to help people living with obesity. Northern Ireland is seeing an increase in obesity rates, with the latest Health Survey NI data showing that 65 per cent of adults and 26 per cent of children in the country are either obese or overweight.

In a recent announcement the Medicines and Healthcare products Regulatory Agency (MHRA) unveiled its strategic approach to artificial intelligence (AI), as it sets out to embrace the transformative potential of AI in healthcare regulation. Building upon the Government's white paper 'A pro-innovation approach to AI regulation', released in 2023, the MHRA outlined five key strategic principles guiding its adoption of AI. These principles encompass safety, security, and robustness; appropriate transparency and explainability; fairness, accountability, and governance; and contestability and redress. A science-led organization, the MHRA was tasked with providing an independent view of its approach to AI in medicine and science, aligning with a government white paper. Recognising its role in UK's goal to be a science and tech leader by 2030, MHRA is tasked to evaluate AI's opportunities and risks across regulatory, public service, and evidence-based decision-making area.

Charac, an NHS-integrated one-stop platform for independent community pharmacies, has secured £1 million strategic investment from the Royal Mail Group, enabling its time-saving platform to assist more local pharmacies and patients across the UK to easily manage their prescriptions and consultations online. The company said this new money will enable it to leverage strong levels of trust that pharmacists enjoy within the communities they serve in and will ensure pharmacies remain a cornerstone of vibrant high streets and an invaluable provider of frontline healthcare products and services, including vitally needed consultations. Charac says it is aiming to sign up over 1,000 UK pharmacies in the next 12 months by expanding its geographic footprint beyond current cities, including London, Manchester and Birmingham, and targeting small multiple and independent pharmacies, accounting for almost 40 per cent of the UK's community pharmacy network. The announcement also sees the addition of Stefan Kulik, a managing director at Royal Mail, to the Charac board. Stefan is responsible for leading Royal Mail's expansion into the healthcare industry and brings a breadth of experience, having previously worked in healthcare with companies including Johnson & Johnson.

Maxwellia has appointed Ian Adamson as strategic advisor to shape the next phase of pharmacy medicine launches - a process which involves identifying and converting suitable prescription only medicines into versions people can choose to buy under the supervision of a pharmacist. Ian brings over 30 years' international consumer health and personal care experience to the Maxwellia team. He is currently an advisor to the board of the UK independent pharmacy chain Day Lewis plc, an advisor to the board of Spanish healthcare company ReVa Europe S.L and board advisor to East Midlands Pharmaceuticals Ltd. Prior to this Ian was Chief Commercial Officer and a main board director at SSL International plc (prior to its sale to Reckitt Benckiser) with responsibility for a $1bn portfolio of brands, which included Durex and Scholl. Ian's appointment follows the landmark reclassification of the progestogen only pill by the MHRA, a change spearheaded by Maxwellia, and the company's subsequent launch of its first product Lovima in July 2021; and the current MHRA public consultation on the reclassification of Maxwellia's new pharmacy brand, Aquiette 2.5mg Tablets (Oxybutynin Hydrochloride) for the treatment of overactive bladder symptoms which are not adequately controlled by bladder training alone.

The All-Party Parliamentary Group (APPG) on Pharmacy published a new report on Monday (January 23) that calls for "urgent action" to relieve funding pressure so there are "opportunities" for community pharmacy teams to deliver even more for their patients. The report highlights the need for a new "strategic vision" for pharmacy and highlights opportunities for the network to be empowered to deliver even more for patients. However, the manifesto also underlines that there are the very real risks that this opportunity may be lost if significant and ongoing pressures are not addressed. The recommendations are based on written and oral evidence gathered from frontline pharmacists, GPs, professional bodies and healthcare experts. To harness the potential of pharmacy, the report recommends the Government must take urgent action to relieve the funding pressures on the community pharmacy sector in the short term and review the long-term funding model for pharmacy. It also suggested the Government must harness the power of pharmacy to help the NHS deal with the COVID-19 backlog and the UK's growing healthcare challenges. It further recommended that future commissioning and funding must recognise that community pharmacy is the front door to the NHS for many patients.

The Federation of Small Businesses (FSB) on Thursday (4 December) announced a new strategic partnership with the Bank of England to protect small businesses from the risks associated with accepting counterfeit banknotes. Cash is still the number one customer payment method for 25 per cent of small high street businesses, and cash payments are expected to increase during the festive period, according to FSB. By becoming a Strategic Partner of the Bank of England's Banknote Checking Scheme, the organisation is trying to help its members become aware of the use of counterfeit notes, which has reputational and financial impacts. The FSB is encouraging its members to sign up to the Scheme, which offers training materials to staff so they can identify a counterfeit note at point of sale and know what to do with it, as well as stay up to date with best practice and bank note developments.

Haleon, the consumer healthcare giant behind brands like Sensodyne toothpaste and Advil painkillers, has announced plans to shut down its Maidenhead manufacturing site in the UK. This decision will impact 435 employees and comes as part of a broader strategic realignment of the company's global manufacturing operations according to BBC. The Maidenhead facility, which has been in operation for years, manufactures some of Haleon's most popular oral health products, including Sensodyne and Parodontax. However, following a comprehensive review of its manufacturing capabilities, the company has concluded that the site is no longer economically viable. In a statement issued by a spokesperson for Haleon, they stated, "Following a strategic review of our global manufacturing capabilities, we have determined that our Maidenhead site is no longer a viable option for the manufacture of our products."

Omnicell UK & Ireland, a leading provider of pharmacy and nursing care automation solutions, has announced a strategic partnership with Gollmann to integrate the German manufacturers' advanced robotic storage and dispensing technology into its retail and central pharmacy solutions portfolio. This collaboration aims to address the increasing pressure on community pharmacies and hospitals to enhance patient safety and meet strict regulatory standards while improving operational efficiency. By combining Omnicell's extensive expertise with Gollmann's innovative technology, the partnership intends to streamline real-time medication dispensing and loading activities, thereby delivering improved workflows and outcomes. Nnamdi Njoku, executive vice president and chief operating officer of Omnicell, highlighted the company's commitment to providing software and automation solutions to ensure "safe, efficient medication and supply management across the healthcare continuum." "Through strategic relationships with technology leaders like Gollmann, and others announced earlier this month with TrackTraceRX, LSPedia, and Follett, we are growing our solutions portfolio as we seek to meet the evolving needs of our global customers, while being focused on driving greater efficiency and working to improve patient safety across hospital and retail settings," he said.

Black Haircare Market Report covers key strategic developments of the market including acquisitions & mergers, new type launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the black haircare market on a global and regional basis. To give the users of this report a comprehensive view on the black haircare market competitive landscape and analysis of Porter's Five Forces model for the market are included in the report. The study encompasses market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.

In its effort to address workforce challenges, Health Education and Improvement Wales has outlined initiatives aimed at facilitating the return of pharmacy professionals with refugee status to active practice within Wales. This possibility has been stated in HEIW's Strategic Pharmacy Workforce Plan, which commits to investigating the practicality and significance of establishing a registration pathway for pharmacy professionals displaced due to refugee status. According to HEIW, it is currently investigating the viability and importance of revitalising 'return to practice' packages, formulating pharmacy apprenticeships, initiating international recruitment initiatives, and establishing a registration pathway in Wales for displaced pharmacists and pharmacy technicians holding refugee status. "In the past two years, we have arrived at a point where maintaining the desired access to the volume and quality of pharmacy services for our population has proven unattainable," said HEIW. "In Wales, instances of diminished pharmacy services are evident in both hospital and community settings. The trend of abrupt, temporary closures in community pharmacies continues."

PAGB, the prominent consumer healthcare association, has appointed a new Vice-President following the departure of Richard Holme from PAGB's Board earlier this year. Brian R. Fischel, who currently serves as Regional Director & General Manager for UK and Ireland at Reckitt, is set to take on the new Vice-President role at PAGB. Bringing extensive international experience as Vice-President at UK trade association representing manufacturers of branded over-the-counter medicines, medical devices and food supplements, Fischel has over eight years at Reckitt managing various global health territories. His election in the leadership role in June positions him alongside Bas Vorsteveld, President, and Mike Knowland, Vice President, completing PAGB's executive team. Michelle Riddalls, CEO of PAGB, expressed optimism about Brian's appointment, emphasising his alignment with PAGB's strategic objectives.

Do you have a small living space such as an apartment? Or a main room in your house that is difficult to decorate and utilize due to its less than desirable square footage? There are strategic tips - ways to trick the eye - to make the space actually appear larger.

Insights Care is honored to present "The 20 Leading Healthcare Solution Providers 2017" which are adapting novel technologies to meet and exceed the health care standard. We have, on our cover, Validic - a cloud-based platform and the market leader in health data connectivity that provides healthcare organizations access to personal health data, gathered from FDA-listed in-home medical devices, wearables and healthcare apps. Led by company's CEO and co-founder, Drew Schiller, Validic serves as a technical partner and strategic advisor, guiding its clients through digital health data integration and innovation. At Validic, Drew leads corporate strategy, drives key initiatives and works closely with senior executives at partner organizations to stay ahead of the technology curve. He believes that digital health will reshape healthcare.

West Shell III, the Co-Founder, CEO and Chairman, is a 5-time serial entrepreneur. He is a creative, high-energy leader with a background in strategic marketing and a successful track record of building high growth, innovative companies with passionate employees and committed customers.

Global pharmaceutical and biotechnology company AstraZeneca has signed an agreement with Scorpion Therapeutics to discover, develop and commercialize precision medicines against cancer proteins. The collaboration, announced today (January 13), will focus on a class of proteins called transcription factors, which can regulate important cellular processes including cell growth and survival. Many transcription factors have been identified earlier, but were considered 'undruggable' using conventional drug discovery approaches, the company said in a statement. Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "Unlocking potentially transformative biology is pivotal for delivering the next wave of cancer treatments. "Scorpion's innovative platform is a strong strategic fit as we explore a range of new modalities across our broad drug discovery toolbox with promise to disrupt the activity of these highly-validated cancer targets."

The General Pharmaceutical Council is in the process of appointing five new council members within the next two years, coinciding with the conclusion of the current members' terms. The regulator aims to recruit five individuals from diverse professional and personal backgrounds for its governing council, the GPhC has said. "We are seeking three members to join us in April 2024 and two in April 2025," said GPhC in its job advertisement brief. "For the 2024 intake, two of the new council members must be lay members of the public, while one must be a Saxton . Moreover, at least one out of the three must primarily reside or work wholly or mostly in Wales. As for the new members commencing in 2025, one must be a lay member, and the other must be a registrant member." The members will be initially appointed for a three-year term, with the option to extend their position for a maximum of eight years, GPhC added. The council, which serves as the regulator's governing body, currently comprises 14 members. Half of the council consists of lay members, who bolster public confidence and infuse novel viewpoints into the GPhC, as highlighted by the regulator. "This council will play a pivotal role in shaping the regulatory body's future strategic goals," the regulator added. "These members must contribute positively to patients and society, ensuring the benefits of secure and efficient pharmacy care."

Rosalind Brewer, the CEO of Walgreens Boots Alliance, Inc. (WBA), the parent company of Boots UK, has resigned from her position after serving for less than three years. The prominent US pharmaceutical company is currently in the process of searching for her successor. Ginger Graham, the lead independent director, has been appointed as the interim CEO. "WBA's board of directors and Brewer have mutually agreed on her departure as chief executive and board member," the company said in a statement. Brewer officially stepped down from her roles as chief executive and director on Thursday (Aug. 31). She assumed the CEO role in March 2021, succeeding Executive Chairman Stefano Pessina. Prior to this, Brewer held the position of CEO at Starbucks. The leadership change aligns with WBA's shift towards becoming a broader healthcare company, a strategic move initiated by Brewer and her team in October 2021.